Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 680 across all filing types
Latest filing 2023-01-23 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a letter addressed to stock exchanges regarding the earnings call for the quarter and nine months ended December 31, 2022. It mentions that the audio recording of the earnings call has been uploaded on the company's website and provides a weblink. The document does not contain the transcript or detailed financial data but is an announcement about the availability of the earnings call recording. The document length is short (1378 characters), and it serves as an informational notice rather than the actual earnings release or call transcript. Therefore, it fits best under the category of Call Transcript (CT) as it relates to the earnings call, but since it only announces the recording and does not provide the transcript itself, the closest appropriate classification is Regulatory Filings (RNS) as a general regulatory announcement about the earnings call recording availability.
2023-01-23 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled as an "Investor Presentation on Q3FY23 (Quarter and Nine Months ended December 31, 2022) Financial Results" and is dated January 23, 2023. It contains detailed financial data such as EBITDA, PBT, PAT, margins, cash flow, operational highlights, and segment revenue breakdowns. The content is structured as a presentation with charts and tables summarizing quarterly and nine-month financial performance, business updates, and growth drivers. It is not a full annual report, audit report, or earnings release but a detailed presentation aimed at investors about the company's quarterly financial results and strategic updates. The document is over 12,000 characters, indicating it is substantive and not merely an announcement or a brief summary. Therefore, the appropriate classification is Investor Presentation (IP).
2023-01-23 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated January 23, 2023, announcing the Q3FY23 (quarter and nine months ended December 31, 2022) financial results of Gland Pharma Limited. It contains detailed financial data including revenue, EBITDA, PBT, PAT, segment-wise revenue, R&D expenses, and capex. It also mentions an upcoming earnings call to discuss the results. The document is about quarterly financial results with substantive financial data and analysis, not just a brief announcement or summary. It is not a full annual report but a quarterly update. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2023
2023-01-23 English
Financial Result Updates
Interim / Quarterly Report Classification · 100% confidence The document is a detailed communication from Gland Pharma Limited dated January 23, 2023, addressed to stock exchanges, reporting the outcome of a Board Meeting. It specifically mentions the approval of unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31, 2022, along with the Limited Review Report. The document includes the auditor's review report pursuant to Regulation 33 of SEBI Listing Obligations and Disclosure Requirements, which pertains to interim financial results. The presence of detailed financial data for the quarter and nine months, the auditor's review, and the reference to Indian Accounting Standard 34 (Interim Financial Reporting) confirms this is an Interim / Quarterly Report. The document is about unaudited quarterly and nine-month financial results, not a full annual report or just an announcement. Therefore, the correct classification is Interim / Quarterly Report (IR). The document length (15,000 characters) and content confirm it is a substantive financial report, not merely an announcement or certification. 9M 2023
2023-01-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a notification about an upcoming Earnings Conference Call scheduled for January 23, 2023, to discuss the company's financial performance for the third quarter ended December 31, 2022. It includes details about the call timing, dial-in information, and mentions that the transcript and audio recording will be made available on the company's website. The document does not contain actual financial data or results but is an announcement of the call event. Therefore, it is classified as a Call Transcript (CT) related announcement, but since it is only announcing the call and not the transcript itself, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about the earnings call event.
2023-01-06 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal letter from the company to stock exchanges informing about an upcoming Board Meeting scheduled for January 23, 2023, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2022. It also mentions the reopening of the trading window and an investor/analyst earnings call on the same day. The document does not contain the financial results themselves but is an announcement of the meeting and related events. The document length is short (2058 characters) and serves as an intimation rather than the actual financial report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and notification under SEBI regulations, not the actual Interim/Quarterly Report or Earnings Release.
2023-01-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.